高纯度尿促性素(Menotropins) - 药物靶点：FSHR x LHCGR_在研适应症：原发性卵巢功能不全，女性不育伴无排卵，多内分泌代谢卵巢综合征_专利_临床

概要

基本信息

药物类型

化学药

别名

Gonadoryl、Highly Purified Menotrophin、HMG

+ [12]

靶点

FSHR x LHCGR

作用方式

激动剂、刺激剂

作用机制

FSHR激动剂(卵泡刺激素受体激动剂)、LHCGR激动剂(促黄体激素/绒毛膜促性腺激素受体激动剂)、卵泡刺激

治疗领域

肿瘤内分泌与代谢疾病泌尿生殖系统疾病

在研适应症

原发性卵巢功能不全女性不育伴无排卵多内分泌代谢卵巢综合征+ [3]

非在研适应症

男性不育症

原研机构

FERRING BV

在研机构

Ferring Pharmaceuticals Pty Ltd.

辉凌医药咨询（上海）有限公司Ferring Pharmaceuticals, Inc.

非在研机构

Ferring Pharmaceuticals A/S

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1999-08-27),

女性不孕症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 3246α

Sequence Code 3253β

Sequence Code 83626β

关联

142

项与高纯度尿促性素相关的临床试验

NCT07691073

/ Not yet recruiting临床4期IIT

The Impact of Ovarian Stimulation With hMG on Embryo Quality in Advanced Age Women. A Randomized Controlled Trial

Ovarian stimulation (OS) is a key component of IVF, aimed at increasing oocyte yield and improving embryo development potential. While early protocols relied solely on FSH, newer approaches incorporate hMG and LH-based stimulation, allowing more individualized treatments for specific patient populations. Evidence suggests that hMG and recombinant FSH (rFSH) have comparable effectiveness in stimulation outcomes, and current guidelines support the use of both. However, the impact of different gonadotropins on embryo quality remains unclear, with mixed findings across protocols. Given the increasing use of combined rFSH and hMG and the limited data in PPOS protocols, this study proposes a randomized controlled trial to compare embryo quality between two different rFSH-hMG dosing strategies.

开始日期2026-09-01

申办/合作机构

Ferring Pharmaceuticals SA

NCT07568574

/ Enrolling by invitationN/A

Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes: A Hybrid Design in a Real-World Setting

Objectives:
The primary objective is to assess the safety and tolerability of medical drugs with the potential to enhance performance (PES) in professional athletes over a 5.5 year period, encompassing a 25-week PES Exposure period and 5 year long term follow-up of period comprehensive health and safety monitoring. The secondary objective is to evaluate the impact of PES on athletic performance through validated sport specific and clinical assessments.
Methods:
This prospective hybrid design study will enrol 60 adult participants, divided into two groups. The first group will receive performance-enhancing substances (PES) directly through the study, administered as Investigational Medicinal Products (IMPs) under comprehensive medical supervision for up to 25 weeks. The second group will include natural athletes and those already using PES prescribed by their own doctors. All substances used in this study are medically approved by national regulatory agencies (e.g., FDA, MHRA, EMA, EDE, etc.), and market authorised.
Participants undergo enrollment and baseline health and performance assessments, prior to a 25 weeks of PES exposure. During the period of PES exposure, participants undergo periodic monitoring of comprehensive physiological biomarkers alongside subjective assessments. Following the PES exposure phase, participants will complete repeat baseline health and performance assessments, followed by a titration phase and, where indicated, post-cycle therapy (PCT) to support the restoration of physiological function toward baseline. The study will conclude with a five-year longitudinal follow-up period to monitor long-term health outcomes. During this phase, participants will undergo annual assessments, including cardiac electrocardiography (ECG), echocardiography, magnetic resonance imaging (MRI), blood and urine biomarkers, routine vital signs, and quality-of-life measures. Additional imaging will include brain functional MRI (fMRI) and vital organ ultrasound at years 1, 3, and 5, with cardiac CT performed as clinically indicated. Athlete safety biomarker assessments, clinical evaluations, and adverse event reporting, will be continuously evaluated by study doctors and with additional safety oversight from a Data Safety Monitoring Board, Independent Medical Commission (a multidisciplinary panel of medical experts), and a Medical Monitor.

开始日期2026-03-12

申办/合作机构-

ChiCTR2500113652

/ SuspendedN/AIIT

Comparison of Clinical Outcomes between the GnRH Agonist Protocol and the Intensified Oestrogen Administration Protocol in Frozen Embryo Transfer Cycles for Patients with Thin Endometrium: A Prospective Randomized Controlled Study

开始日期2025-12-01

申办/合作机构

温州医科大学附属第一医院

100 项与高纯度尿促性素相关的临床结果

登录后查看更多信息

100 项与高纯度尿促性素相关的转化医学

登录后查看更多信息

100 项与高纯度尿促性素相关的专利（医药）

登录后查看更多信息

2,236

项与高纯度尿促性素相关的文献（医药）

2026-08-01·Ophthalmology science

Deep Learning and Radiomics Assessment for Highly Myopic Glaucoma Detection Based on Fundus Photography

Article

作者: Wang, Yizhou ; Li, Zhidong ; Zhu, Yingting ; Chen, Xiaohong ; Zuo, Chenguo ; Zhuo, Yehong ; Zhao, Xiujuan ; Chen, Xuhao ; Hu, Lingjing ; Han, Wenjing ; Huang, Shaofen ; Luo, Man ; Lu, Lin ; Zhou, Chen ; Xiao, Hui

Purpose:

To investigate spatially distinctive features in fundus photographs of highly myopic glaucoma (HMG) by integrating radiomics and deep learning.

Design:

Cross-sectional study.

Participants:

Semi-automated optic disc segmentation was performed on 2000 images sourced from the Retinal Fundus Glaucoma Challenge Edition and Pathologic Myopia Challenge public data sets. We trained models with 628 images, including 217 cases of high myopia (HM), 221 cases of primary open-angle glaucoma (POAG), and 190 cases of HMG. An external validation set of 106 images was collected including 31, 36, and 39 fundus photographs from patients with HM, HMG, and POAG, respectively.

Methods:

Semi-automated optic disc segmentation was performed by U-Net combined with manual delineation. Additionally, 5 regions of interest (ROIs) covering the optic disc and its surrounding region were explored. Fundus photography-based radiomics feature selection and optimization were conducted using random forest and support vector machine algorithms, which underwent fivefold cross-validation. Model performance was evaluated for radiomics, clinical, and combined models. An external validation set was used to evaluate the models performance, and we also examined radiomics features varied across glaucoma stages.

Main Outcome Measures:

A total of 414 radiomics features were extracted from 5 regions of interest. We evaluated the model performance using accuracy, recall, precision, F1 score, and area under the receiver operating characteristic curve (AUROC). The Youden index was used to determine the cut-off value, and sensitivity and specificity were calculated.

Results:

The U-Net-based optic disc segmentation reached a Dice Similarity Coefficient of 0.95. The radiomics model detected HMG from HM and POAG achieved the accuracies of 0.97 and 0.85, respectively. Both results exceeded the performance of the clinical model, which achieved 0.90 and 0.71. The top radiomics features achieved AUROC of 0.984 and 0.855 for HMG versus HM and HMG versus POAG in the external validation, respectively, including intensity features in the extra-optic nerve and textural features in the optic nerve. These features showed strong diagnostic capability when stratified by Youden values and exhibited independence from glaucoma progression.

Conclusions:

The study combined U-Net and radiomics to delineate the spatial distribution biomarkers of HMG, establishing a quantitative classification model correlated with anatomical features.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

2026-08-01·REPRODUCTIVE BIOMEDICINE ONLINE

A plan for universal access to fertility care

Review

作者: Sable, David

In the 66 years since the introduction of clomiphene citrate, the 64 years since the first pregnancy using menotrophin stimulation and the 48 years since the birth of the first baby conceived through IVF, the procedures that have been developed to help millions of families to overcome infertility have become increasingly safe and effective. Our ability to provide access to the much larger population of underserved and unserved has, however, lagged far behind. As declining fertility rates bring renewed attention to access to fertility care, the challenge for reproductive medicine is to leverage the progress made in developing safe and effective treatment and make it universally available to those patients in need. This requires a strategy to address both cost of care and treatment capacity constraints, challenges made less daunting due to recent innovation and technology.

2026-07-01·BREAST CANCER RESEARCH AND TREATMENT

Assisted Reproductive Technologies (ART) and breast cancer risk: hormonal treatments under the spotlight

Review

作者: Lia, Francesca L ; Boldrini, Cristiana ; Bottalico, Micol ; Longo, Valentina ; Gigli, Silvia

Abstract:

Background:

Assisted Reproductive Technologies (ART) have become nowadays a cornerstone in the management of infertility. While these treatments are generally considered safe, concerns have been raised regarding their potential influence on breast cancer (BC) risk, particularly in specific subgroups of women.

Objective:

This narrative review aims to evaluate the most relevant past and current literature on the association between ART-related hormonal treatments and breast cancer risk, highlighting potential biological mechanisms, epidemiological evidence, and clinical implications.

Methods:

A literature search was conducted through PubMed, focusing on medium-to-large cohort and case-control studies, meta-analyses, and guidelines published to date. Evidence was synthesized by distinguishing overall ART/IVF risk estimates from drug-specific findings and subgroup-specific risk modifiers. Particular attention was given to the most recent or most comprehensive reports when multiple publications were derived from the same cohort.

Results:

To date, current evidence does not support a real and consistent overall increase in breast cancer risk following ART-related hormonal treatments. Large population-based studies and recent meta-analyses are generally reassuring, particularly when ART-treated women are compared with infertile untreated women rather than with the general population. Some studies report modest risk elevations in selected subgroups, including nulliparous or nulligravid women, women undergoing repeated or high-dose stimulation cycles, and women with hereditary BC predisposition; however, these findings are inconsistent and often limited by residual confounding, small subgroup numbers, and incomplete dose information. Progesterone supplementation appears safe in the context of ART, with no consistent evidence of increased BC risk. Gonadotropins, including hMG, may transiently increase estrogen exposure, but large-scale studies and meta-analyses generally do not confirm a long-term increase in breast cancer incidence.

47

项与高纯度尿促性素相关的新闻（医药）

2026-09-07

·小信Healthcare

【国信医药|财报点评】丽珠集团（000513.SZ）：2026年上半年业绩承压，莱康奇塔单抗获批上市

分析师：陈曦炳 S0980521120001 分析师：彭思宇 S0980521060003 分析师：肖婧舒 S0980525070001 报告发布日期：2026年9月3日注：公众号仅展示部分内容，报告全文可扫描二维码阅读核心观点公司2026年上半年业绩承压 2026年上半年公司实现营收50.00亿元（-20.3%），归母净利润9.32亿元（-27.2%），扣非归母净利润8.90亿元（-29.3%），2026年第二季度营收21.29亿元（-31.1%），归母净利润3.55亿元（-44.9%），扣非归母净利润3.12亿元（-51.3%），主要由于公司重点品种艾普拉唑钠系列、注射用尿促性素等受医保价格影响，销售收入下滑，注射用亮丙瑞林广东联盟地区销售收入大幅下滑，马来酸氟伏沙明片自今年开始执行第十一批国家集采，销售收入下滑，导致公司上半年业绩承压。公司核心品种进展顺利接棒原有产品带来增量公司在消化、精神神经、生殖、心脑血管领域布局多款创新产品。消化领域，接续品种JP-1366片（P-CAB）反流性食管炎适应症处于上市审评阶段，联合抗生素用于幽门螺杆菌根除适应症已经完成临床3期首例患者给药，注射剂型针对消化性溃疡出血适应症已启动临床3期研究。生殖领域，注射用亮丙瑞林微球（3M）处于上市申报审评阶段，有望年内获批；曲普瑞林微球中枢性早熟适应症即将完成临床3期研究；重组人促卵泡激素注射液已于2026年6月获批上市；口服GnRH拮抗剂LPM7100328辅助生殖适应症已经启动临床3期研究。精神神经领域，NS-041（KCNQ2/3激动剂）癫痫适应症推进至临床2期阶段；布瑞哌唑微球已经启动临床1期研究，并于7月完成首例患者给药。自免和代谢领域，莱康奇塔单抗（IL-17A/F抗体）在银屑病适应症与司库奇尤单抗头对头比较显示出优效，2026年8月在国内获批上市，强直性脊柱炎适应症的临床3期研究取得良好的结果；司美格鲁肽用于糖尿病适应症已经处于上市审评阶段，减重适应症的上市申请已获受理。心血管领域，H001（凝血酶IIa因子抑制剂）已经完成针对全膝关节置换术患者的临床2期研究；引进产品LZSN2501（FXI双抗）用于成人全膝关节置换术后静脉血栓栓塞症的临床IND已于2026年8月提交并获受理。风险提示商业化进度不及预期，创新药研发进度不及预期。正文内容 2026年上半年公司实现营收50.00亿元（-20.3%），归母净利润9.32亿元（-27.2%），扣非归母净利润8.90亿元（-29.3%），2026年第二季度营收21.29亿元（-31.1%），归母净利润3.55亿元（-44.9%），扣非归母净利润3.12亿元（-51.3%），主要由于公司重点品种艾普拉唑系列、注射用尿促性素等受医保价格影响，销售收入下滑，注射用亮丙瑞林广东联盟地区销售收入大幅下滑，马来酸氟伏沙明片自今年开始执行第十一批国家集采，销售收入下滑，导致公司上半年业绩承压。公司优化营销体系，销售费用率下降。2026年上半年，公司实现毛利率61.3%（-4.74pp），销售净利率22.4%（-2.31pp）；销售/管理/研发/财务费用率分别为23.0%/5.4%/7.2%/0.3%，分别同比-4.7pp/+0.6pp/+0.3pp/+2.9pp。公司核心品种进展顺利，接棒原有产品带来增量。公司在消化、精神神经、生殖、心脑血管领域布局多款创新产品。消化领域，接续品种JP-1366片（P-CAB）反流性食管炎适应症处于上市审评阶段，联合抗生素用于幽门螺杆菌根除适应症已经完成临床3期首例患者给药，注射剂型针对消化性溃疡出血适应症已启动临床3期研究。生殖领域，注射用亮丙瑞林微球（3M）处于上市申报审评阶段，有望年内获批；曲普瑞林微球中枢性早熟适应症即将完成临床3期研究；重组人促卵泡激素注射液已于2026年6月获批上市；口服GnRH拮抗剂LPM7100328辅助生殖适应症已经启动临床3期研究。精神神经领域，NS-041（KCNQ2/3激动剂）癫痫适应症推进至临床2期阶段；布瑞哌唑微球已经启动临床1期研究，并于7月完成首例患者给药。自免和代谢领域，莱康奇塔单抗（IL-17A/F抗体）在银屑病适应症与司库奇尤单抗头对头比较显示出优效，2026年8月在国内获批上市，强直性脊柱炎适应症的临床3期研究取得良好的结果；司美格鲁肽用于糖尿病适应症已经处于上市审评阶段，减重适应症的上市申请已获受理。心血管领域，H001（凝血酶IIa因子抑制剂）已经完成针对全膝关节置换术患者的临床2期研究；引进产品LZSN2501（FXI双抗）用于成人全膝关节置换术后静脉血栓栓塞症的临床IND已于2026年8月提交并获受理。相关研究报告国信医药团队法律声明本公众号（名称：【小信Healthcare】）为国信证券股份有限公司（下称“国信证券”）经济研究所【医药】组设立并独立运营的唯一官方公众号。本公众号所载内容仅面向符合《证券期货投资者适当性管理办法》规定的专业投资者。国信证券不因任何订阅或接收本公众号内容的行为而将订阅人视为国信证券的客户。本公众号不是国信证券研究报告的发布平台，本公众号只是转发国信证券发布研究报告的部分观点，订阅者若使用本公众号所载资料，有可能会因缺乏对完整报告的了解而对其中关键假设、评级、目标价等内容产生误解和歧义。提请订阅者参阅国信证券已发布的完整证券研究报告，仔细阅读其所附各项声明、信息披露事项及风险提示，关注相关的分析、预测能够成立的关键假设条件，关注投资评级和证券目标价格的预测时间周期，并准确理解投资评级的含义。国信证券对本公众号所载资料的准确性、可靠性、时效性及完整性不作任何明示或暗示的保证。本公众号中资料、意见等仅代表来源证券研究报告发布当日的判断，相关研究观点可依据国信证券后续发布的证券研究报告在不发布通知的情形下作出更改。国信证券的销售人员、交易人员以及其他专业人士可能会依据不同假设和标准、采用不同的分析方法而口头或书面发表与本公众号中资料意见不一致的市场评论和/或观点。本公众号所载信息、意见不构成所述证券或金融工具买卖的出价或询价，评级、目标价、估值、盈利预测等分析判断亦不构成对具体证券或金融工具在具体价位、具体时点、具体市场表现的投资建议。该等信息、意见在任何时候均不构成对任何人的具有针对性的、指导具体投资的操作意见，订阅者应当对本公众号中的信息和意见进行评估，根据自身情况自主做出投资决策并自行承担投资风险。订阅者根据本公众号内容做出的任何决策与国信证券或相关作者无关。本公众号发布的内容仅为国信证券所有。未经国信证券事先书面许可，任何机构和/或个人不得以任何形式转发、翻版、复制、发布或引用本公众号发布的全部或部分内容，亦不得从未经国信证券书面授权的任何机构、个人或其运营的媒体平台接收、翻版、复制或引用本公众号发布的全部或部分内容。国信证券将保留追究一切法律责任的权利。

财报临床3期临床2期临床申请申请上市

2026-09-04

·腾讯自选股

2026年上半年业绩承压，莱康奇塔单抗获批上市

丽珠集团(000513)核心观点公司2026年上半年业绩承压。2026年上半年公司实现营收50.00亿元（-20.3%），归母净利润9.32亿元（-27.2%），扣非归母净利润8.90亿元（-29.3%），2026年第二季度营收21.29亿元（-31.1%），归母净利润3.55亿元（-44.9%），扣非归母净利润3.12亿元（-51.3%），主要由于公司重点品种艾普拉唑钠系列、注射用尿促性素等受医保价格影响，销售收入下滑，注射用亮丙瑞林广东联盟地区销售收入大幅下滑，马来酸氟伏沙明片自今年开始执行第十一批国家集采，销售收入下滑，导致公司上半年业绩承压。公司核心品种进展顺利，接棒原有产品带来增量。公司在消化、精神神经、生殖、心脑血管领域布局多款创新产品。消化领域，接续品种JP-1366片（P-CAB）反流性食管炎适应症处于上市审评阶段，联合抗生素用于幽门螺杆菌根除适应症已经完成临床3期首例患者给药，注射剂型针对消化性溃疡出血适应症已启动临床3期研究。生殖领域，注射用亮丙瑞林微球（3M）处于上市申报审评阶段，有望年内获批；曲普瑞林微球中枢性早熟适应症即将完成临床3期研究；重组人促卵泡激素注射液已于2026年6月获批上市；口服GnRH拮抗剂LPM7100328辅助生殖适应症已经启动临床3期研究。精神神经领域，NS-041（KCNQ2/3激动剂）癫痫适应症推进至临床2期阶段；布瑞哌唑微球已经启动临床1期研究，并于7月完成首例患者给药。自免和代谢领域，莱康奇塔单抗（IL-17A/F抗体）在银屑病适应症与司库奇尤单抗头对头比较显示出优效，2026年8月在国内获批上市，强直性脊柱炎适应症的临床3期研究取得良好的结果；司美格鲁肽用于糖尿病适应症已经处于上市审评阶段，减重适应症的上市申请已获受理。心血管领域，H001（凝血酶IIa因子抑制剂）已经完成针对全膝关节置换术患者的临床2期研究；引进产品LZSN2501（FXI双抗）用于成人全膝关节置换术后静脉血栓栓塞症的临床IND已于2026年8月提交并获受理。投资建议：略微下调盈利预测，维持“优于大市”评级。公司2026年上半年受到核心品种被纳入集采和医保目录等因素影响，业绩承压，考虑到公司处于创新转型的阶段，略微下调盈利预测，预计2026-2028年公司营收分别为100.49/102.42/106.36亿元（前值123.04/127.67/134.62亿元），同比-16.4%/+1.9%/+3.9%，归母净利润分别为17.82/19.82/22.73亿元（前值20.76/23.68/27.60亿元），同比-11.9%/+11.2%/+14.7%，当前股价对应PE=13.2/11.9/10.4x，维持“优于大市”评级。风险提示：商业化进度不及预期，创新药研发进度不及预期。

临床3期财报临床2期上市批准临床申请

2026-09-04

·东方财富网

2026年上半年业绩承压，莱康奇塔单抗获批上市

丽珠集团(000513) 核心观点公司2026年上半年业绩承压。2026年上半年公司实现营收50.00亿元（-20.3%），归母净利润9.32亿元（-27.2%），扣非归母净利润8.90亿元（-29.3%），2026年第二季度营收21.29亿元（-31.1%），归母净利润3.55亿元（-44.9%），扣非归母净利润3.12亿元（-51.3%），主要由于公司重点品种艾普拉唑钠系列、注射用尿促性素等受医保价格影响，销售收入下滑，注射用亮丙瑞林广东联盟地区销售收入大幅下滑，马来酸氟伏沙明片自今年开始执行第十一批国家集采，销售收入下滑，导致公司上半年业绩承压。公司核心品种进展顺利，接棒原有产品带来增量。公司在消化、精神神经、生殖、心脑血管领域布局多款创新产品。消化领域，接续品种JP-1366片（P-CAB）反流性食管炎适应症处于上市审评阶段，联合抗生素用于幽门螺杆菌根除适应症已经完成临床3期首例患者给药，注射剂型针对消化性溃疡出血适应症已启动临床3期研究。生殖领域，注射用亮丙瑞林微球（3M）处于上市申报审评阶段，有望年内获批；曲普瑞林微球中枢性早熟适应症即将完成临床3期研究；重组人促卵泡激素注射液已于2026年6月获批上市；口服GnRH拮抗剂LPM7100328辅助生殖适应症已经启动临床3期研究。精神神经领域，NS-041（KCNQ2/3激动剂）癫痫适应症推进至临床2期阶段；布瑞哌唑微球已经启动临床1期研究，并于7月完成首例患者给药。自免和代谢领域，莱康奇塔单抗（IL-17A/F抗体）在银屑病适应症与司库奇尤单抗头对头比较显示出优效，2026年8月在国内获批上市，强直性脊柱炎适应症的临床3期研究取得良好的结果；司美格鲁肽用于糖尿病适应症已经处于上市审评阶段，减重适应症的上市申请已获受理。心血管领域，H001（凝血酶IIa因子抑制剂）已经完成针对全膝关节置换术患者的临床2期研究；引进产品LZSN2501（FXI双抗）用于成人全膝关节置换术后静脉血栓栓塞症的临床IND已于2026年8月提交并获受理。投资建议：略微下调盈利预测，维持“优于大市”评级。公司2026年上半年受到核心品种被纳入集采和医保目录等因素影响，业绩承压，考虑到公司处于创新转型的阶段，略微下调盈利预测，预计2026-2028年公司营收分别为100.49/102.42/106.36亿元（前值123.04/127.67/134.62亿元），同比-16.4%/+1.9%/+3.9%，归母净利润分别为17.82/19.82/22.73亿元（前值20.76/23.68/27.60亿元），同比-11.9%/+11.2%/+14.7%，当前股价对应PE=13.2/11.9/10.4x，维持“优于大市”评级。风险提示：商业化进度不及预期，创新药研发进度不及预期。

100 项与高纯度尿促性素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02692	高纯度尿促性素	G03GA02	DB00032

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
原发性卵巢功能不全	美国	Ferring Pharmaceuticals, Inc.	2014-02-19
女性不育伴无排卵	澳大利亚	Ferring Pharmaceuticals Pty Ltd.	2011-09-13
多内分泌代谢卵巢综合征	澳大利亚	Ferring Pharmaceuticals Pty Ltd.	2011-09-13
无排卵	美国	Ferring Pharmaceuticals, Inc.	2004-10-29
不孕	美国	Ferring Pharmaceuticals, Inc.	2004-10-29
女性不孕症	美国	Ferring Pharmaceuticals, Inc.	1999-08-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
男性不育症	临床3期	比利时	Ferring Pharmaceuticals A/S	2009-07-01
男性不育症	临床3期	捷克	Ferring Pharmaceuticals A/S	2009-07-01
男性不育症	临床3期	丹麦	Ferring Pharmaceuticals A/S	2009-07-01
男性不育症	临床3期	波兰	Ferring Pharmaceuticals A/S	2009-07-01
男性不育症	临床3期	西班牙	Ferring Pharmaceuticals A/S	2009-07-01
男性不育症	临床3期	瑞典	Ferring Pharmaceuticals A/S	2009-07-01
男性不育症	临床3期	土耳其	Ferring Pharmaceuticals A/S	2009-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05103228 (CTgov)	N/A	不孕 \| 卵巢储备减少 \| 卵巢疾病	190	human menopausal gonadotropin+Follitropin delta+Follitropin Alfa (Lower Gonadotropin Dose Stimulation)	簾繭夢襯糧襯窪壓簾顧 = 製廠襯壓鹹觸窪鹽醖遞窪鹹鑰夢築憲積餘網齋 (蓋壓廠淵範壓餘積艱夢, 鬱憲構鹹網淵艱網襯蓋 ~ 鹽觸獵構廠網鑰積鹽鏇) 更多	-	2024-12-13
				human menopausal gonadotropin+Follitropin delta+Follitropin Alfa (Higher Gonadotropin Dose Stimulation)	簾繭夢襯糧襯窪壓簾顧 = 淵窪憲憲選鹹淵艱築齋窪鹹鑰夢築憲積餘網齋 (蓋壓廠淵範壓餘積艱夢, 廠糧願憲壓選積餘獵襯 ~ 壓製餘構壓遞網壓鬱構) 更多
NCT04163458 (CLARA, CTgov)	临床3期	不孕 \| 男性不育症	405	Placebo (for MENOPUR powder and solvent for solution for injection)+MENOPUR (MENOPUR Liquid)	壓襯構蓋壓憲鹹夢積鹽(鬱艱餘醖範鬱觸遞願鹹) = 築鏇構衊窪構獵鹹遞鬱網糧獵糧餘廠觸醖製廠 (構構衊鬱衊蓋餘鹽餘簾, 5.5) 更多	-	2023-11-07
				Placebo (for MENOPUR solution for injection in pre-filled pen)+MENOPUR powder and solvent for solution for injection, 75 IU (MENOPUR Powder)	壓襯構蓋壓憲鹹夢積鹽(鬱艱餘醖範鬱觸遞願鹹) = 構餘壓鏇鬱簾衊衊獵膚網糧獵糧餘廠觸醖製廠 (構構衊鬱衊蓋餘鹽餘簾, 4.2) 更多
NCT02554279 (MEGASET-HR, Pubmed)	临床4期	-	620	Highly purified human menotropin (HP-hMG)	願鬱醖糧艱鏇衊構鹹獵(範鏇醖繭製餘願壓構餘) = 齋淵襯顧顧壓顧網遞構淵積觸膚醖獵繭淵積遞 (齋構襯艱築餘願憲蓋觸 )	-	2020-12-01
				Recombinant follicle-stimulating hormone (FSH)	願鬱醖糧艱鏇衊構鹹獵(範鏇醖繭製餘願壓構餘) = 憲憲膚蓋衊衊範獵獵齋淵積觸膚醖獵繭淵積遞 (齋構襯艱築餘願憲蓋觸 )
NCT02554279 (MEGASET HR, Pubmed \| Fertil Steril) 人工标引	临床4期	卵巢刺激	619	highly purified human menotropin	艱願製選範範構膚選鹹(衊鏇網顧糧繭膚艱範蓋) = 繭夢鹹鹽願繭遞憲獵齋範襯糧淵遞糧廠廠廠鏇 (醖簾襯襯積範憲鬱獵襯 ) 更多	不佳	2020-08-01
				recombinant follicle-stimulating hormone	艱願製選範範構膚選鹹(衊鏇網顧糧繭膚艱範蓋) = 蓋願膚網壓鬱獵製鬱衊範襯糧淵遞糧廠廠廠鏇 (醖簾襯襯積範憲鬱獵襯 ) 更多
NCT02554279 (MEGASET-HR \| MEGASET HR, CTgov)	临床4期	不孕	620	menotropin (Menotropin)	廠夢蓋醖鹹鬱獵憲夢齋 = 獵築衊憲築願襯鹽網壓顧壓廠製齋願範鏇餘選 (醖積顧壓廠廠鑰憲淵淵, 願獵蓋艱淵憲願簾簾鏇 ~ 衊膚艱積糧繭範鬱壓網) 更多	-	2018-03-02
				recombinant FSH (Recombinant FSH)	廠夢蓋醖鹹鬱獵憲夢齋 = 夢網選願鏇醖艱窪獵選顧壓廠製齋願範鏇餘選 (醖積顧壓廠廠鑰憲淵淵, 鹽築積壓餘夢壓襯醖顧 ~ 壓顧襯遞範顧願廠獵壓) 更多
NCT01921166 (Diminished Ovarian Reserve, CTgov)	临床4期	不孕	23	Menopur+Clomid+Bravelle+Follistim+Gonal f (Clomiphene Plus Gonadotropins)	鹽願廠餘襯繭餘壓積願 = 顧鹹願夢構糧構網鹹構廠廠鑰觸鬱餘鹽選夢膚 (願顧鬱網觸淵餘壓艱餘, 繭壓願鑰窪蓋廠獵襯壓 ~ 夢鑰齋夢糧淵壓構鬱憲) 更多	-	2018-02-23
				Leuprolide flare (Leuprolide Flare)	鹽願廠餘襯繭餘壓積願 = 膚衊壓壓齋築壓鬱網淵廠廠鑰觸鬱餘鹽選夢膚 (願顧鬱網觸淵餘壓艱餘, 襯鹹築糧廠網糧鹽憲襯 ~ 廠齋淵選築鬱齋蓋鏇顧) 更多
NCT02542280 (CTgov)	临床3期	不孕 \| 子宫内膜炎	360	endometrial injury. (Endometrial Injury)	襯製鬱鑰齋膚淵簾獵選 = 艱鹽夢積獵顧鹽壓鑰鬱顧簾構築獵襯繭顧餘襯 (襯鏇鏇築製簾壓醖鏇衊, 襯餘願積構範齋憲醖廠 ~ 積選糧鑰觸鑰觸鑰齋蓋) 更多	-	2016-01-08
				ovarian stimulation (no Endometrial Injury)	襯製鬱鑰齋膚淵簾獵選 = 鏇積構鏇遞鹹選淵艱顧顧簾構築獵襯繭顧餘襯 (襯鏇鏇築製簾壓醖鏇衊, 夢鹹鬱顧襯觸醖選簾築 ~ 憲製觸廠願膚蓋遞積糧) 更多
NCT01569945 (Pubmed \| Hum Reprod)	N/A	不孕	657	Low-dose human menopausal gonadotrophin	壓獵廠淵鑰鑰簾淵壓鹹(選鑰衊積願顧鬱築齋鑰) = 築鑰鹽積窪醖願遞憲糧夢窪夢遞蓋衊壓夢範獵 (網廠製壓夢襯觸淵窪觸 ) 更多	-	2015-05-01
				Clomiphene citrate	壓獵廠淵鑰鑰簾淵壓鹹(選鑰衊積願顧鬱築齋鑰) = 獵積獵構鹽鑰積夢廠襯夢窪夢遞蓋衊壓夢範獵 (網廠製壓夢襯觸淵窪觸 ) 更多
NCT01312766 (CTgov)	临床3期	不孕	270	Menotropins (hMG-IBSA)	夢廠餘網衊觸醖夢鹹襯(網鹹鬱憲衊築鏇鑰鑰糧) = 淵鹽襯醖齋鹽齋淵鹹夢繭鏇糧積簾齋蓋鏇淵膚 (遞遞簾遞選鬱願製艱糧, 6.6) 更多	-	2014-08-15
				Menotropins (Menopur)	夢廠餘網衊觸醖夢鹹襯(網鹹鬱憲衊築鏇鑰鑰糧) = 鬱壓積積淵鹽艱淵糧憲繭鏇糧積簾齋蓋鏇淵膚 (遞遞簾遞選鬱願製艱糧, 5.9) 更多
NCT01417195 (COMBINE, CTgov)	临床4期	不孕	122	Bravelle+Menopur (Menopur and Bravelle Combination)	鏇餘衊鬱襯淵餘顧顧壓(築構蓋繭獵網選餘製築) = 範鹹鹽鬱淵鏇構窪網遞醖壓壓築鹹鹹顧構願鏇 (鹽選蓋窪糧製鏇鏇製淵, 21.567) 更多	-	2014-04-24
				Menopur (Menopur Alone)	鏇餘衊鬱襯淵餘顧顧壓(築構蓋繭獵網選餘製築) = 淵廠鬱鏇鬱願鏇衊窪遞醖壓壓築鹹鹹顧構願鏇 (鹽選蓋窪糧製鏇鏇製淵, 22.460) 更多